Sanofi (NASDAQ:SNY) Posts Earnings Results, Beats Expectations By $0.48 EPS

Sanofi (NASDAQ:SNY) posted its earnings results on Friday. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.56 by $0.48, Zacks reports. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The company had revenue of $17.25 billion for the quarter, compared to analyst estimates of $14.29 billion. During the same quarter in the prior year, the business posted $2.91 EPS. The firm’s revenue was up 16.2% compared to the same quarter last year.

Here are the key takeaways from Sanofi’s conference call:

• Q3 performance was strong: sales rose 14.3% to €14.4 billion, business operating income increased 19.7%, and business EPS grew 19.6%, supported by demand, favorable gross-to-net adjustments, product mix, and strict cost control.
• Sanofi upgraded its 2026 outlook to sales growth of 13%–15% and business EPS growth of 15%–17%. Management also expects business operating income and margin to increase annually through 2030, despite upcoming headwinds.
• Dupixent remained the central growth engine, generating €5.7 billion in Q3 with more than 1.5 million patients globally. Sanofi reaffirmed confidence in reaching at least €25 billion in annual sales by 2030 and expanded its Regeneron alliance with four next-generation immunology antibodies, including a potential long-acting follow-on product.
• Sanofi is concentrating resources on immunology, rare diseases, and vaccines while pursuing late-stage and commercial assets through disciplined BD and M&A. The company expects to provide more detail on its disease-area priorities, capital allocation, and Dupixent loss-of-exclusivity planning at a strategic update before year-end.
• R&D productivity remains a concern, with management acknowledging that Sanofi’s pipeline lags peers and discontinuing amlitelimab and itepekimab after benefit-risk reviews. The company also cautioned that 2027 sales will face roughly €1.3 billion of divestment-related reductions, a return to slightly negative pricing trends, and continued Dupixent profit-sharing and reimbursement headwinds.

Sanofi Stock Up 2.8%

SNY stock traded up $1.21 during trading on Friday, reaching $44.34. The stock had a trading volume of 15,100,858 shares, compared to its average volume of 3,453,743. Sanofi has a one year low of $39.07 and a one year high of $52.68. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. The company’s 50 day moving average is $42.21 and its two-hundred day moving average is $44.35. The company has a market capitalization of $107.50 billion, a price-to-earnings ratio of 23.21, a P/E/G ratio of 1.33 and a beta of 0.33.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on SNY shares. UBS Group reiterated a “neutral” rating on shares of Sanofi in a research note on Thursday, September 17th. Wolfe Research assumed coverage on Sanofi in a research note on Friday, October 9th. They issued a “peer perform” rating for the company. Weiss Ratings upgraded Sanofi from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. Morgan Stanley set a $49.00 target price on Sanofi in a research report on Wednesday, July 8th. Finally, DZ Bank reiterated a “buy” rating on shares of Sanofi in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Sanofi has an average rating of “Hold” and an average price target of $49.50.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.